CIN No.: L24230TG1995PLC020093



Regd. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA. Admin Office: 3-11-451, L B Nagar, Hyderabad - 500074

E-mail: concorddrugsltd@gmail.com

Ph.No: +91 9052779505

Website: www.concorddrugs.in

To,

Date: 13.02.2024

**BSE** Limited P.J. Towers, Dalal Street Mumbai- 400001

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 13.02.2024

Ref: Our Company's letter dated 06.02.2024

Unit: Concord Drugs Limited (Scrip Code: 538965)

With reference to the subject cited, this is to inform the exchange that the Board of Directors of Concord Drugs Limited at its meeting held on Tuesday, the 13th day of February, 2024 at the registered office of the company at 1:00 p.m., approved the following items of business:

- 1. Un-audited Financial Results (Standalone and Consolidated) for the Quarter ended 31st December, 2023. (Enclosed as Annexure).
- 2. Limited Review Report (Standalone and Consolidated) for the Quarter ended 31st December, 2023. (Enclosed as Annexure).
- 3. Appointment of M/s. Vivek Surana &Associates., practicing company secretaries, as Secretarial Auditor of the Company for the FY 2023-24.(Brief Profile is annexed as Annexure - I)
- 4. Appointment of M/s. Nazeerudeen & Co., Chartered Accountants, as Internal Auditor of the Company for the FY 2023-24.(Brief Profile is annexed as Annexure - II)

The meeting concluded at 5.50 p.m.

This is for the information and records of the Exchanges, please.

Drug.

Thanking you.

Yours sincerely, For Concord Drugs Limited

S. Nagi Reddy

Chairman & Managing Director

(DIN-01764665)

S. Ni rey

Encl. as above

#### Annexure I

Brief Profile of M/s. Vivek Surana & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company

The details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015

Particulars	M/s. Vivek Surana & Associates
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. Vivek Surana & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company.
Date of appointment &Terms of appointment	Appointed on 13.02.2024 for the Financial Year 2023-24
Brief Profile	Vivek Surana & Associates, is a Practicing Company Secretaries firm based at Hyderabad providing secretarial, listing and other advisory services. The firm has existence of more than a decade in the above said services.
Disclosure of relationships between directors (in case of appointment of a director)	NA

#### Annexure II

Brief Profile of M/s. Nazeerudeen & Co.,, as Internal Auditor of the Company

The details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015

Sl.No	Particulars	Details
1.	reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. Nazeerudeen & Co., Chartered Accountants as Internal Auditor of the Company
2.	date of appointment/cessation (as applicable) & term of appointment	Appointed on 13.02.2024 for the Financial Year 2023-24
3.	brief profile (in case of appointment);	Nazeerudeen & Co is a Chartered Accountants firm based at Hyderabad providing accounting, taxation, audit related services.  Mr. Nazeerudeen is having rich experience of more than 10 years in above mentioned services.
4.	disclosure of relationships between directors (in case of appointment of a director).	Not Applicable



CIN No.: L24230TG1995PLC020093



# CONCORD DRUGS LIMITED

Regd. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA. Admin Office: 3-11-451, L B Nagar, Hyderabad - 500074

E-mail: concorddrugsltd@gmail.com

Ph.No: +91 9052779505

Website: www.concorddrugs.in

a. Neb. Ot b. Ot b. Ot other limits a. Carl b. Chemistry and the composition of the compo	Expenses  Offic (Loss) before Exceptional Item and tax (III-IV)  septional Items  offic (Loss) before tax (V-VI)	31-Dec-23 (un Audited) 1,262.435 0.005 1,262.440 1,043.646 120.328 43.176 38.489 41.109 1,287.953 -25.513 -3.566	Quarterly ended 30-Sep-23 [un Audited]  738.23 0.82  739.05  473.67 -44.95 127.83 39.03 38.41 28.81 662.81 76.24	31-Dec-22 (un Audited) 1,352.71 0.12 1,352.83 1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23	Nine mon 31-Dec-23 (un Audited) 2,879.51 0.81 2,880.32 2,091.51 -31.52 369.65 121.25 114.81 100.92	31-Dec-22 (Un Audited) 3,977.42 0.81 3,978.23 2,977.84 44.30 361.86 120.79 129.53	[Rs. in Lake 31-Mar-23 (Audited) 5,131.4 0.8 5,132.3 4,035.5 51.5 463.4
I Rev. a. No b. Ot b. Ot ot c. Em d. Fir e. De f. Other III a. Cur Other III a. Sas b. Dilit Expedies:	Net sales from Operations Other Operating Income her Income tal Revenue (I+II) penses ost of Material Consumed changes in Inventories of finished goods, work-in-progress and stock-in-trade imployees Benefit Expenses Ginance Costs repreciation and Amortisation expense ther expenses tal Expenses tal Expenses offit (Loss) before Exceptional item and tax (III-IV) reptional Items offit (Loss) before tax (V-VI) Expenses Expenses Utrent tax	(un Audited)  1,262.435 0.005  1,262.440  1,043.646 1.206 120.328 43.176 38.489 41.109 1,287.953 -25.513	30-Sep-23 (un Audited) 738.23 0.82 739.05 473.67 -44.95 127.83 39.03 38.41 28.81 662.81	(un Audited)  1,352.71 0.12  1,352.83  1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23	31-Dec-23 (un Audited) 2,879.51 0.81 2,880.32 2,091.51 -31.52 369.65 121.25 114.81	31-Dec-22 (Un Audited) 3,977.42 0.81 3,978.23 2,977.84 44.30 361.86 120.79	5,131, 0,1 5,132,3 4,035,5 51,5
I Rev. a. No b. Ot b. Ot ot c. Em d. Fir e. De f. Other III a. Cur Other III a. Sas b. Dilit Expedies:	Net sales from Operations Other Operating Income her Income tal Revenue (I+II) penses ost of Material Consumed changes in Inventories of finished goods, work-in-progress and stock-in-trade imployees Benefit Expenses Ginance Costs repreciation and Amortisation expense ther expenses tal Expenses tal Expenses offit (Loss) before Exceptional item and tax (III-IV) reptional Items offit (Loss) before tax (V-VI) Expenses Expenses Utrent tax	(un Audited)  1,262.435 0.005  1,262.440  1,043.646 1.206 120.328 43.176 38.489 41.109 1,287.953 -25.513	738.23 0.82 739.05 473.67 -44.95 127.83 39.03 38.41 28.81 662.81	(un Audited)  1,352.71 0.12  1,352.83  1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23	31-Dec-23 (un Audited) 2,879.51 0.81 2,880.32 2,091.51 -31.52 369.65 121.25 114.81	31-Dec-22 (Un Audited) 3,977.42 0.81 3,978.23 2,977.84 44.30 361.86 120.79	5,131. 0.8 5,132.3 4,035.5 51.5
I Rev. a. No b. Ot b. Ot ot c. Em d. Fir e. De f. Other III a. Cur Other III a. Sas b. Dilit Expedies:	Net sales from Operations Other Operating Income her Income tal Revenue (I+II) penses ost of Material Consumed changes in Inventories of finished goods, work-in-progress and stock-in-trade imployees Benefit Expenses Ginance Costs repreciation and Amortisation expense ther expenses tal Expenses tal Expenses offit (Loss) before Exceptional item and tax (III-IV) reptional Items offit (Loss) before tax (V-VI) Expenses Expenses Utrent tax	1,262.435 0.005 1,262.440 1,043.646 1.206 120.328 43.176 38.489 41.109 1,287.953 -25.513	738.23 0.82 739.05 473.67 -44.95 127.83 39.03 38.41 28.81 662.81	(un Audited)  1,352.71  0.12  1,352.83  1,002.88  -32.00  130.63  44.92  37.97  106.83  1,291.23	2,879.51 0.81 2,880.32 2,091.51 -31.52 369.65 121.25 114.81	(Un Audited) 3,977,42 0.81 3,978.23 2,977.84 44.30 361.86 120.79	5,131. 0.8 5,132.3 4,035.5 51.5
a. Neb. Ot b. Ot b. Ot other limits a. Carl b. Chemistry and the composition of the compo	Net sales from Operations Other Operating Income her Income tal Revenue (I+II) penses ost of Material Consumed changes in Inventories of finished goods, work-in-progress and stock-in-trade imployees Benefit Expenses Ginance Costs repreciation and Amortisation expense ther expenses tal Expenses tal Expenses offit (Loss) before Exceptional item and tax (III-IV) reptional Items offit (Loss) before tax (V-VI) Expenses Expenses Utrent tax	0.005 1,262.440 1,043.646 1,206 120.328 43.176 38.489 41.109 1,287.953 -25.513	0.82 739.05 473.67 -44.95 127.83 39.03 38.41 28.81 662.81	1,352.71 0.12 1,352.83 1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23	2,879.51 0.81 2,880.32 2,091.51 -31.52 369.65 121.25 114.81	3,977.42 0.81 3,978.23 2,977.84 44.30 361.86 120.79	5,131. 0.8 5,132.3 4,035.5 51.5
II Other III III III Expe a.Cos b. Ch c. Em d. Fir e. De f. Oth Total Profit III a. Cu b. Delt Items Total comp Total comp Total comp Items Total comp Items Total comp Items Total comp Items Total comp total c	Other Operating Income her Income tal Revenue (I+II) penses ost of Material Consumed changes in Inventories of finished goods, work-in-progress and stock-in-trade imployees Benefit Expenses finance Costs repreciation and Amortisation expense ther expenses tal Expenses fit/ (Loss) before Exceptional item and tax (III-IV) reptional Items for item (IV-VI) CEXPENSES CERTIFICATION OF THE PROPERTY OF	0.005 1,262.440 1,043.646 1,206 120.328 43.176 38.489 41.109 1,287.953 -25.513	0.82 739.05 473.67 -44.95 127.83 39.03 38.41 28.81 662.81	0.12 1,352.83 1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23	2,880.32 2,091.51 -31.52 369.65 121.25 114.81	0.81 3,978.23 2,977.84 44.30 361.86 120.79	5,132. 4,035. 51.
III Other Total IV Experience a.Cos b. Ch c. Err d. Fir e. Dee f. Oth Tota Profit Exce VV Profit IT ax IV III a. Cur Other Items Total (Face Other III a. Bas b. Dilt  tes:	her Income tal Revenue (I+II) peenses ost of Material Consumed Changes in Inventories of finished goods, work-in-progress and stock-in-trade imployees Benefit Expenses Finance Costs Depreciation and Amortisation expense ther expenses tal Expenses fit/ (Loss) before Exceptional item and tax (III-IV) septional Items offit/ (Loss) before tax (V-VI) Expenses:	1,262.440 1,043.646 1,206 120.328 43.176 38.489 41.109 1,287.953 -25.513	0.82 739.05 473.67 -44.95 127.83 39.03 38.41 28.81 662.81	0.12 1,352.83 1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23	2,880.32 2,091.51 -31.52 369.65 121.25 114.81	0.81 3,978.23 2,977.84 44.30 361.86 120.79	5,132. 4,035. 51.
III Total IV Expe a.Cos b. Ch c. Em d. Fir e. De f. Other IT Tax H a. Cur Other Items Total comp To	tal Revenue (I+II) penses ost of Material Consumed changes in Inventories of finished goods, work-in-progress and stock-in-trade imployees Benefit Expenses chance Costs repreciation and Amortisation expense ther expenses tal Expenses off / (Loss) before Exceptional item and tax (III-IV) reptional Items offit/ (Loss) before tax (V-VI) of Expenses urrent tax	1,043.646 1.206 120.328 43.176 38.489 41.109 1,287.953 -25.513	739.05 473.67 -44.95 127.83 39.03 38.41 28.81 662.81	1,352.83 1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23	2,880.32 2,091.51 -31.52 369.65 121.25 114.81	3,978.23 2,977.84 44.30 361.86 120.79	5,132. 4,035. 51.
IV Experiments of the composition of the compositio	penses ost of Material Consumed Changes in Inventories of finished goods, work-in-progress and stock-in-trade imployees Benefit Expenses Finance Costs repreciation and Amortisation expense ther expenses tal Expenses fift/ (Loss) before Exceptional item and tax (III-IV) reptional Items fift/ (Loss) before tax (V-VI) Expense: urrent tax	1,043.646 1.206 120.328 43.176 38.489 41.109 1,287.953 -25.513	473.67 -44.95 127.83 39.03 38.41 28.81 662.81	1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23	2,091.51 -31.52 369.65 121.25 114.81	2,977.84 44.30 361.86 120.79	4,035. 51.
a.Cos b. Ch c. Em d. Fir e. De f. Oth Tota Profit A. Cur Oth IT Tax I III J. Cur Other Items Total (Face Other III J. Bas b. Dilu tes:	ost of Material Consumed Changes in Inventories of finished goods, work-in-progress and stock-in-trade imployees Benefit Expenses Finance Costs experientation and Amortisation expense ther expenses tal Expenses fit/ (Loss) before Exceptional item and tax (III-IV) experional Items fiti/ (Loss) before tax (V-VI) Expense: urrent tax	1.206 120.328 43.176 38.489 41.109 1,287.953 -25.513	-44.95 127.83 39.03 38.41 28.81 662.81	-32.00 130.63 44.92 37.97 106.83 1,291.23	2,091.51 -31.52 369.65 121.25 114.81	2,977.84 44.30 361.86 120.79	4,035. 51.
b. Ch c. Err d. Fir e. De f. Oth Tota Profit Exce VI Profit JIII a. Cui Other Items Total comp KI Profit Comp KI Profit A. Bas b. Dillu tes:	Changes in Inventories of finished goods, work-in-progress and stock-in-trade imployees Benefit Expenses inance Costs perpendiction and Amortisation expense ther expenses tal Expenses fit/ (Loss) before Exceptional item and tax (III-IV) septional Items of the fit (Loss) before tax (V-VI) taxpenses taxpenses fit/ (Loss) before tax (V-VI) taxpenses fit/ (Loss) before tax (V-VI) taxpenses	1.206 120.328 43.176 38.489 41.109 1,287.953 -25.513	-44.95 127.83 39.03 38.41 28.81 662.81	-32.00 130.63 44.92 37.97 106.83 1,291.23	-31.52 369.65 121.25 114.81	44.30 361.86 120.79	51.5
d. Fire e. De f. Other Total Profit A. Curl Total Profit A. Curl Other Total Comp X Other Items Total (Face Other III Earn IIII a. Bas b. Dilk tes:	imployees Benefit Expenses Finance Costs Pepreciation and Amortisation expense ther expenses tal Expenses offit/ (Loss) before Exceptional item and tax (III-IV) reptional Items fift/ (Loss) before tax (V-VI) Expense: urrent tax	120.328 43.176 38.489 41.109 1,287.953 -25.513	127.83 39.03 38.41 28.81 662.81	130.63 44.92 37.97 106.83 1,291.23	-31.52 369.65 121.25 114.81	44.30 361.86 120.79	51.
d. Fire e. De f. Other transfer of the f. Othe	Finance Costs  lepreclation and Amortisation expense ther expenses tal Expenses offit/ (Loss) before Exceptional item and tax (III-IV) septional Items offit/ (Loss) before tax (V-VI)  Expense: urrent tax	43.176 38.489 41.109 1,287.953 -25.513	39.03 38.41 28.81 662.81	44.92 37.97 106.83 1,291.23	369.65 121.25 114.81	361.86 120.79	
e. De f. Oth Total Profit Avenue 1	pereciation and Amortisation expense ther expenses tal Expenses offit (Loss) before Exceptional item and tax (III-IV) teptional Items offit (Loss) before tax (V-VI) tExpense: Urrent tax	38.489 41.109 1,287.953 -25.513 -25.513	38.41 28.81 662.81	37.97 106.83 1,291.23	121.25 114.81	120.79	403.
f. Oth Tota Profil Tax I Tota Profil Tax I Tota I T T T T T T T T T T T T T T T T T T	ther expenses tal Expenses filt/(Loss) before Exceptional item and tax (III-IV) filt/(Loss) before tax (V-VI) tExpense: tExpense: urrent tax	41.109 1,287.953 -25.513 - -25.513	28.81 662.81	106.83 1,291.23	114.81	The second second	162.4
Total Profit Exce VV Profit Tax I VIII a. Cur 0 b. Del IX Profit X Other Items Total comp (Face Other III a. Bas b. Dilutes:	tal Expenses offt/ (Loss) before Exceptional item and tax (III-IV) septional Items offit/ (Loss) before tax (V-VI) sExpense: urrent tax	1,287.953 -25.513 -25.513	662.81	106.83 1,291.23			160.2
Profit V Exce Profit VIII a. Cur O b. Def IX Profit XX Other Items Total comp Qther (Face Other a. Bas b. Dilt  tes:	ofit/ (Loss) before Exceptional item and tax (III-IV) septional Items ofit/ (Loss) before tax (V-VI) Expense: urrent tax	-25.513 - -25.513		1,291.23		233.09	
V Exce Profit VII Tax k (III) 0 b. Def IX Profit X Other Items Total comp Add (Face Other III a. Bas b. Dilt  tes:	eptional Items filt/ (Loss) before tax (V-VI) c Expense: urrent tax	-25.513	76.24		2,766.60	3,867.41	146.5
VI Profit Tax I Ta	fit/ (Loss) before tax (V-VI)  Expense:  urrent tax	-25.513			113.72	-	5,019.7
VIII Tax Is a. Cur of a. Cur of the comp of the comp of the cur of	Expense: urrent tax			01.00	113.72	110.82	112.5
VIII a. Cur b. Del b. D	urrent tax	-1.566	76.24	61.60	113.72		52
0 b. DeilX Profit Profi			23.61	16.17	36.38	110.82	112.5
X Profit X Other Items Total comp Paid (Face Other IIII IIII IIII IIII IIII IIII IIII I	elerred tax charge/credit	-0.429	24.72	16.68	41.81	28.54	23.3
X Other Items Total comp Paid (Face Other Earni III a. Basi b. Dilu tes:	GLI (I	-1.137	-1.11	-0.51	11/1/2007/81	32.38	34.7
Items Total comp Paid (Face Other Earni III a. Bas b. Dilu tes:	fit/ (Loss) for the period (VII-VIII)	-23.946	52.63	45.43	-5.43 77.34	-3.84	-11.4
Total comp Paid (Face Other III Earni III a. Bas. b. Dilu tes:	er Comprehensive Income	-		43.43	11.34	82.28	89.23
(Face Other Earni a. Basi b. Dilu	ns that will not be reclassified to profit or loss			ŝW	*	*	120
(Face Other Earni a. Basi b. Dilu	al Comprehensive Income for the period (comprising profit and other	250.00 (0000000)			5.	*	12
(Face Other Earni a. Bas b. Dilu	prehensive income for the period) (IX+X)	-23.946	52.63	45.430	77.34	82.280	89.2
Other Earni a. Bas b. Dilu	d up Capital	1,000.000	931.55	874.38	1.000.00	001.00	0.000
III Earni a. Bas b. Dilu	e value of the share- Rs. 10 each)	1 243	701100	074.30	1,000.00	874.38	931.55
a. Bas b. Dilu tes:	er Equity	2,417.184	2,382,52	2,147.60			
a. Bas b. Dilu tes:	nings per share (of Rs. 10 each)	77,77,120,1	2,302.32	2,147.60	2,417.18	2,147.600	2,238.88
tes:	asic (in Rs)	-0.24	0.54	NAME OF THE OWNER, WHEN THE OW			
	luted (in Rs)	-0.24	0.56	0.52	0,77	0.94	0.96
		-0.24	0.56	0.52	0.77	0.94	0.96
1 The fin	finnacial results of the company have been prepared in accordance with the Indian Ai ant rules issued there under.						
releva	ant rules issued there under.	counting Standards (	Ind AS) prescribed u	nder section 133 of	the Companies	Act, 2013, read wi	th the
The ab	above standalone financial results as reviewed by the audit and the	AND DESCRIPTION OF THE PARTY OF					
?	above standalone financial results as reviwed by the audit committee have been app	oved by Board of Dire	ectors at its meeting	held on 13.02.2024	4		
rigures	es of the corresponding previous periods are regrouped and reclassified wherever co	nsidered necessary to	correspond with cu	rrent period's pres	entation		
				and period a presi	emation.		
Ine res	esults are also available on the webiste of the Company www.concorddrugs.in						
	9					y Order of the Bo	
					Fo	or Concord Drugs	

Managing Director DIN: 01764665



Date: 13th February ,2024

# CONCORD DRUGS LIMITED

Regd. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA. Admin Office: 3-11-451, L B Nagar, Hyderabad - 500074

E-mail: concorddrugsltd@gmail.com

Ph.No: +91 9052779505

Website: www.concorddrugs.in

Quarterly ended 30-Sep-23 (Un Audited) 751.67 0.81 752.48 488.08 -78.94 146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	31-Dec-22 (Un Audited) 1,352.71 0.12 1,352.83 1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51	31-Dec-23 (Un Audited) 2,928.21	3,977.42 (Un Audited) 3,977.42 0.81 3,978.23 2,977.84 44.30 361.86 120.79 129.53 233.09 3,867.41 110.82 28.54 32.38 3.84 82.28	Rs. in Lakh 31-Mar-23 (Audited) 5,208.0 0,8 5,208.9 4,116.16 -15.6 491.90 170.6 162.56 158.4 5,084.05 124.89 26.34 37.87 -11.53
30-Sep-23 (Un Audited)  751.67 0.81  752.48  488.08 -78.94 146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	(Un Audited)  1,352.71 0.12  1,352.83  1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	31-Dec-23 (Un Audited)  2,928.21 0.81  2,929.02  2,182.66 -182.53 438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	31-Dec-22 (Un Audited) 3,977.42 0.81 3,978.23 2,977.84 44.30 361.86 120.79 129.53 233.09 3,867.41 110.82 28.54 32.38 3.84 82.28	(Audited) 5,208.0 0.8 5,208.9 4,116.1 -15.6 491.9 170.6 162.5 158.4 5,084.05 124.85 26.34 37.87 -11.53 98.55
(Un Audited)  751.67 0.81  752.48  488.08 -78.94 146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	(Un Audited)  1,352.71 0.12  1,352.83  1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	(Un Audited)  2,928.21 0.81  2,929.02  2,182.66 -182.53 438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	(Un Audited) 3,977.42 0.81 3,978.23 2,977.84 44.30 361.86 120.79 129.53 233.09 3,867.41 110.82 28.54 32.38 3.84 82.28	(Audited) 5,208.0 0.8 5,208.9 4,116.1 -15.6 491.9 170.6 162.5 158.4 5,084.0 124.8 26.34 37.83 -11.53 98.55
751.67 0.81 752.48 488.08 -78.94 146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	1,352.71 0.12 1,352.83 1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	2,928.21 0.81 2,929.02 2.182.66 -182.53 438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	3,977.42 0.81 3,978.23 2,977.84 44.30 361.86 120.79 129.53 233.09 3,867.41 110.82 110.82 28.54 32.38 3.84 82.28	5,208.0 0,8 5,208.9 4,116.1 -15.6 491.9 170.6 162.5 158.4 5,084.0 124.8 26.34 37.87 -11.53 98.55
0.81 752.48 488.08 -78.94 146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	0.12 1,352.83 1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	0.81 2,929.02 2,182.66 -182.53 438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	0.81 3,978.23 2,977.84 44.30 361.86 120.79 129.53 233.09 3,867.41 110.82 28.54 32.38 3.84 82.28	0.8 5,208.9 4,116.1 -15.6 491.9 170.6 162.5 158.4 5,084.0 124.8 26.34 37.80 -11.53 98.55
0.81 752.48 488.08 -78.94 146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	0.12 1,352.83 1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	0.81 2,929.02 2,182.66 -182.53 438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	0.81 3,978.23 2,977.84 44.30 361.86 120.79 129.53 233.09 3,867.41 110.82 28.54 32.38 3.84 82.28	0,8 5,208.9 4,116.1 -15.6 491.9 170.6 162.5 158.4 5,084.0 124.8 26.3 37.8 -11.5 98.55
752.48  488.08 -78.94 146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	1,352.83  1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	2,929.02  2,182.66 -182.53 438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	3,978.23  2,977.84  44.30  361.86 120.79 129.53 233.09 3,867.41 110.82 110.82 28.54 32.38 3.84 82.28	5,208.9 4,116.1 -15.6 491.9 170.6 162.5 158.4 5,084.0 124.8 26.34 37.80 -11.53 98.55
488.08 -78.94 146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	1,002.88 -32.00 130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	2,182.66 -182.53 438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	2,977.84 44.30 361.86 120.79 129.53 233.09 3,867.41 110.82 28.54 32.38 82.28	4,116.1 -15.6 491.9 170.6 162.5 158.4 5,084.0 124.8 26.3 37.8 -11.5 98.55
-78.94 146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	-32.00 130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	2,182.66 -182.53 438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	2,977.84 44.30 361.86 120.79 129.53 233.09 3,867.41 110.82 28.54 32.38 82.28	4,116.1 -15.6 491.9 170.6 162.5 158.4 5,084.0 124.8 26.3 37.8 -11.5 98.55
-78.94 146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	-32.00 130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	-182.53 438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	44.30 361.86 120.79 129.53 233.09 3,867.41 110.82 110.82 28.54 32.38 32.88	-15.6 491.9 170.6 162.5; 158.4 5,084.03 124.89 26.34 37.85 -11.53 98.55
146.33 42.65 38.83 35.73 672.68 79.80 23.62 24.72 -1.10 56.18	130.63 44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	44.30 361.86 120.79 129.53 233.09 3,867.41 110.82 110.82 28.54 32.38 32.88	-15.6 491.9 170.6 162.5; 158.4 5,084.03 124.89 26.34 37.85 -11.53 98.55
42.65 38.83 35.73 672.68 79.80 79.80 23.62 24.72 -1.10 56.18	44.92 37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	438.57 136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	361.86 120.79 129.53 233.09 3,867.41 110.82 110.82 28.54 32.38 3.84 82.28	491.9 170.6 162.5 1584.0 124.8 124.8 26.3 37.8 -11.5 98.5
38.83 35.73 672.68 79.80 79.80 23.62 24.72 -1.10 56.18	37.97 106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	136.38 116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	120.79 129.53 233.09 3,867.41 110.82 28.54 32.38 3.84 82.28	170.6 162.5 158.4 5,084.0 124.8 26.34 37.8 -11.53
35.73 672.68 79.80 79.80 23.62 24.72 -1.10 56.18	106.83 1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	116.10 120.21 2,811.39 117.63 36.51 41.94 -5.44 81.12	129.53 233.09 3,867.41 110.82 110.82 28.54 32.38 -3.84 82.28	162.5i 158.49 5,084.05 124.89 124.89 26.34 37.87 -11.53 98.55
672.68 79.80 79.80 23.62 24.72 -1.10 56.18	1,291.23 61.60 61.60 16.17 16.68 -0.51 45.43	120.21 2,811.39 117.63 117.63 36.51 41.94 -5.44 81.12	233.09 3,867.41 110.82 110.82 28.54 32.38 -3.84 82.28	158.4 5,084.05 124.85 124.85 26.34 37.85 -11.53 98.55
79.80 79.80 23.62 24.72 -1.10 56.18	61.60 61.60 16.17 16.68 -0.51 45.43	2,811.39 117.63 117.63 36.51 41.94 -5.44 81.12	3,867.41 110.82 110.82 28.54 32.38 -3.84 82.28	5,084.05 124.89 124.89 26.34 37.87 -11.53 98.55
79.80 23.62 24.72 -1.10 56.18	61.60 16.17 16.68 -0.51 45.43	117.63 117.63 36.51 41.94 -5.44 81.12	110.82 110.82 28.54 32.38 -3.84 82.28	124.89 124.89 26.34 37.87 -11.53 98.55
23.62 24.72 -1.10 56.18	16.17 16.68 -0.51 45.43	117.63 36.51 41.94 -5.44 81.12	110.82 28.54 32.38 -3.84 82.28	124.85 26.34 37.87 -11.53 98.55
23.62 24.72 -1.10 56.18	16.17 16.68 -0.51 45.43	36.51 41.94 -5.44 81.12	28.54 32.38 -3.84 82.28	26.34 37.87 -11.53 98.55
24.72 -1.10 56.18	16.68 -0.51 45.43	41.94 -5.44 81.12	28.54 32.38 -3.84 82.28	26.34 37.87 -11.53 98.55
-1.10 56.18	-0.51 45.43	-5.44 81.12	32.38 -3.84 82.28	37.87 -11.53 98.55
56.18 56.18	45.43	81.12	-3.84 82.28	-11.53 98.55
56.18		*	347	98.55
			347	123
	-	-		
	1000 1500			
	45.43			
	43,43	81.12	82.28	98.55
931.55	874.38	1,000.00	874.38	931.55
NEW CONTRACTOR				
2,382.52	2,147.60	2,417.05	2,147.60	2,238.88
0.60	0.52	0.81	0.94	1.06
0.60	0.52	0.81	0.94	1.06
(Ind AS) prescribed	under section 133	of the Companie	s Act, 2013, read	with the
Directors at its meet	ing held on 13th Fe	bruary, 2024		
			ares of Re 283 and	h ) frankrij
olidated intoo the o	perations of compa	any from march 2	3,2023 onwards.	,,,,urtiser
f	f Directors at its meet	f Directors at its meeting held on 13th Fe	f Directors at its meeting held on 13th February, 2024  try to correspond with current period's presentation.  or a total consideration of 1,41,50,000 (50,000 equity shinsolidated into the operations of company from march 2	



## PUNDARIKASHYAM AND ASSOCIATES

### CHARTERED ACCOUNTANTS

# 1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet, Hyderabad, Telangana - 500016. Cell: 9440464339, Ph: 040-35175033

E-mail: info@pkas.in / infoong@pkas.in

GSTIN: 36AAJFP6218J1ZY

Branches: 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.

2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.

3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

### To the Board of Directors of Concord Drugs Limited,

- 1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 31 December 203, and the year to date results for the period 1 April 2023 to 31 December 2023, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
- 2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we



would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pundarikashyam and Associates

Chartered Accountants

Firm Regn. No.011330S

B. Surya Prakasa Rao

Partner

Membership No.205125

UDIN: 24205125BKADD x 2299

HYDERABAD

Place: Hyderabad

Date: 13.02.2024



## PUNDARIKASHYAM AND ASSOCIATES

### CHARTERED ACCOUNTANTS

# 1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet, Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033

E-mail: info@pkas.in / infoong@pkas.in GSTIN: 36AAJFP6218J1ZY

Branches: 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.

2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.

3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Consolidated Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

- 1. We have reviewed the accompanying statement of Consolidated unaudited financial results ('the Statement') of Concord Drugs Limited ('the group company') for the quarter ended 31 December 2023, and the year to date results for the period 1 April 2023 to 31 December 2023, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
- 2. The statement, which is the responsibility of the Group Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act'),SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'),and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we



would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

HYDERABAD

For Pundarikashyam and Associates

Chartered Accountants

Firm Regn. No.011330S

B. Surya Prakasa Rao

Partner

Membership No.205125

UDIN: 24205125BK

Place: Hyderabad

Date: 13.02.2024,